If we build it they will come: targeting the immune response to breast cancer

Historically, breast cancer tumors have been considered immunologically quiescent, with the majority of tumors demonstrating low lymphocyte infiltration, low mutational burden, and modest objective response rates to anti-PD-1/PD-L1 monotherapy. Tumor and immunologic profiling has shed light on poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatti-Mays, Margaret E., Balko, Justin M., Gameiro, Sofia R., Bear, Harry D., Prabhakaran, Sangeetha, Fukui, Jami, Disis, Mary L., Nanda, Rita, Gulley, James L., Kalinsky, Kevin, Abdul Sater, Houssein, Sparano, Joseph A., Cescon, David, Page, David B., McArthur, Heather, Adams, Sylvia, Mittendorf, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820540/
https://www.ncbi.nlm.nih.gov/pubmed/31700993
http://dx.doi.org/10.1038/s41523-019-0133-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820540/
https://www.ncbi.nlm.nih.gov/pubmed/31700993
http://dx.doi.org/10.1038/s41523-019-0133-7

Ejemplares similares